Abstract
The title compound, C29H42N4O5·0.5H2O, comprises four structural units. A flexible prop-yloxy unit in a gauche conformation, with a -C(H2)-C(H2)-C(H2)-O- torsion angle of -64.32 (18)°, connects an isoxazole ring and an approximately planar phenyl-oxa-diazole ring system [with a maxixmum devation of 0.061 (2) Å], which are oriented almost parallel to one another with a dihedral angle of 10.75 (7)°. Furthermore, a C11-alkyl chain with a terminal hy-droxy group links to the 3-position of the isoxazole ring via an amide bond. In the crystal, a half-occupancy solvent water mol-ecule connects to a neighbouring mol-ecule via an inter-molecular O-H⋯O(water) hydrogen bond to the C11-alkyl chain hy-droxy group.
Highlights
C(H2)—O– torsion angle of 64.32 (18), connects an isoxazole ring and an approximately planar phenyloxadiazole ring system [with a maxixmum devation of 0.061 (2) Å], which are oriented almost parallel to one another with a dihedral angle of 10.75 (7)
Was developed against various human illnesses caused by enteroviruses including common respiratory infections, rash or mild fever and serious or life-threatening infections, such as meningitis, myocarditis, encephalitis and paralytic poliomyelitis (De Palma et al, 2008; Diana, 2003)
The antiviral drug candidate development led to the WIN 63843 analogue, better known as Pleconaril, which showed a drastic decrease in the metabolic degradation of the molecule and a broad range of antiviral activity against enteroviruses (Pevear et al, 1999; Wildenbeest et al, 2012)
Summary
Was developed against various human illnesses caused by enteroviruses including common respiratory infections, rash or mild fever and serious or life-threatening infections, such as meningitis, myocarditis, encephalitis and paralytic poliomyelitis (De Palma et al, 2008; Diana, 2003). The antiviral drug candidate development led to the WIN 63843 analogue, better known as Pleconaril, which showed a drastic decrease in the metabolic degradation of the molecule and a broad range of antiviral activity against enteroviruses (Pevear et al, 1999; Wildenbeest et al, 2012). The design of the title compound is based on the chemical structure of the WIN 61893 analogue (Diana et al, 1995), to which an additional C11-alkyl linker arm having a hydroxy end group was attached at the 3-position of the isoxazole ring via an amide bond.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
